This federal Cooperative Agreement award, funded by the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) program, is intended to scale up and improve the management of drug-resistant tuberculosis (DR-TB) in USAID-supported countries. The $287,878,180 award, effective from October 1, 2024 to September 30, 2029, will focus on expanding access to high-quality DR-TB treatment services and providing specialized technical...
The U.S. Agency for International Development (USAID) awarded a $4,650,276 Cooperative Agreement under the Foreign Assistance for Programs Overseas (CFDA 98.001) program to JSI Research & Training Institute Inc., a non-profit organization based in Boston, Massachusetts. The agreement, titled "CURE TUBERCULOSIS PROJECT 2", is for a 5-year period from August 2024 to August 2029 and aims to: 1) Improve diagnostic and laboratory network performance to increase tuberculosis (TB) case...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $13,095,236 Cooperative Agreement to the World Health Organization (WHO) under the Global Tuberculosis: Developing, Evaluating, Implementing Evidence-based and Innovative Approaches to Find, Cure, and Prevent Tuberculosis Globally program (CFDA 93.494). The award duration is from September 30, 2024 to September 29, 2029. The funding supports WHO's efforts to develop, evaluate, and implement evidence-based and innovative...
This Cooperative Agreement, awarded by the U.S. Agency for International Development (USAID) under the Foreign Assistance for Programs Overseas (CFDA 98.001) program, provides $31,253,928 in funding to the Centre For Health Solutions - Kenya, a non-profit organization, to support the Kenyan Ministry of Health in controlling and preventing tuberculosis (TB) over a 5-year period from May 2024 to May 2029. The award will fund comprehensive TB prevention, care, and treatment activities, including...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $6,749,031 Cooperative Agreement under the Global AIDS program (CFDA 93.067) to the Association de Sante Familiale (ASF), a local non-profit organization, and PATH, a U.S.-based international NGO, for the USHINDI project. The project aims to enhance access to HIV services and achieve epidemic control in seven health zones in Haut-Katanga Province, Democratic Republic of the Congo (DRC). The key objectives include increasing case...
This $560,420 Cooperative Agreement, awarded by the Centers for Disease Control and Prevention (CDC) under the Project Grants and Cooperative Agreements for Tuberculosis Control Programs (CFDA 93.116), supports the Alabama Department of Public Health (ADPH) in conducting comprehensive tuberculosis (TB) prevention, control, and elimination activities throughout the state. The award period runs from January 1, 2025 to December 31, 2029. The key products and services to be delivered under this...
This Cooperative Agreement award from the Department of Health and Human Services Centers for Disease Control and Prevention (CFDA 93.940 - HIV Prevention Activities Health Department Based) provides $178,443 to the State of North Carolina Department of Health & Human Services (NC DHHS) to bolster its tuberculosis (TB) prevention and control efforts. The funding will support a comprehensive strategy to quickly diagnose and treat TB disease, promptly investigate contacts of infectious TB...
The Hawaii Department of Health received a $219,938 cooperative agreement from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Health Department Based program (CFDA 93.940). The award will fund comprehensive tuberculosis (TB) control and elimination efforts in the state of Hawaii from January 1, 2025 to December 31, 2029. Key activities include TB screening, diagnosis, treatment of latent TB infection and active TB disease, contact investigations,...
The Chicago Department of Public Health (CDPH) was awarded a 5-year Cooperative Agreement totaling $100,316 from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Health Department Based program (CFDA 93.940). The funding supports CDPH's Tuberculosis Elimination Program, which works to save lives and improve health by curing, preventing, and eventually eliminating TB among Chicago residents and visitors. Key program activities include nurse case management,...
The Centers for Disease Control and Prevention (CDC) has awarded a $103,744 Cooperative Agreement (CFDA 93.940 - HIV Prevention Activities Health Department Based) to the Indiana Department of Health (IDOH) to assist with addressing the strategies and implementing the activities identified in the state's application. The funding will allow IDOH to continue and initiate new prevention and control (P&C) activities as well as laboratory strengthening initiatives to address the increasing...
APPLICATION FOR THE CDC TECHNICAL ASSISTANCE SERVICES AND PROGRAMMATIC SUPPORT TO ADDRESS NATIONAL TB PROGRAM NEEDS AND PRIORITIES TOWARDS THEIR EFFORTS TO END TB AWARD. - PATH WILL PARTNER WITH CDC AND GOVERNMENTS, SPECIFICALLY NATIONAL TB PROGRAMS (NTPS), IN INDIA, TANZANIA, AND ZAMBIA TOWARD ACHIEVING A WORLD FREE OF TB BY ACCELERATING PROGRESS TOWARD THE GLOBAL END TB TARGETS AND REDUCING TRANSMISSION AND MORBIDITY AMONG GROUPS AT HIGHER RISK FOR DEVELOPING TB DISEASE: HOUSEHOLD CONTACTS OF PEOPLE WITH TB, CHILDREN AND ADOLESCENTS, PEOPLE LIVING WITH HIV, HEALTH CARE WORKERS, MIGRANTS, MOBILE/DISPLACED POPULATIONS, AND THOSE WHO WORK/LIVE IN CROWDED AND/OR CONGREGATE SETTINGS (E.G., CRIMINAL JUSTICE FACILITIES, MINES, HIGH-DENSITY HOUSING AREAS). PATH WILL PROVIDE TECHNICAL ASSISTANCE (TA) WHILE BUILDING ON OUR RECENT AND CURRENT TB AND CAPACITY-STRENGTHENING WORK IN THESE COUNTRIES AND ALIGNING WITH WHO'S END TB STRATEGY, THE STOP TB PARTNERSHIP GLOBAL PLAN TO END TB (20232030), UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS FOR TB, THE UNITED NATIONS POLITICAL DECLARATION ON THE FIGHT AGAINST TB (2018), AND PEPFAR. THESE THREE COUNTRIES REMAIN HIGH-BURDEN SETTINGS FOR TB AND HIV-ASSOCIATED TB DESPITE PROGRESS MADE OVER THE YEARS BY THEIR TB PROGRAMS. PATH WILL FOSTER COLLABORATION ACROSS COUNTRIES TO ENABLE SHARING OF THEIR DIFFERENT EXPERIENCES AND STRENGTHS: LEVERAGING INDIA'S EXPERIENCES AS EARLY ADOPTERS OF NOVEL TB DIAGNOSTIC TOOLS AND TREATMENT REGIMENS, TANZANIA'S EXPERIENCE IN PATIENT DATA MANAGEMENT SYSTEMS, AND ZAMBIA'S EXPERIENCE BUILDING A RESILIENT SYSTEM FOR TB DURING COVID-19. PATH'S WORK WILL BE LED BY OUR PRINCIPAL INVESTIGATOR/PROJECT DIRECTOR, DR. STOBDAN KALON, WHO HAS 25 YEARS OF EXPERIENCE MANAGING COMPLEX PROGRAMS IN THE AREAS OF TB AND HIV IN CENTRAL ASIA, SOUTH AND SOUTHEAST ASIA, AND AFRICA. TOGETHER WITH NTPS, PATH WILL IMPLEMENT A COMPREHENSIVE TA APPROACH TO ADDRESS TB PROGRAMMING NEEDS AND PRIORITIES, WHICH WILL INCLUDE PROBLEM PRIORITIZATION AND ROOT CAUSE ANALYSIS. OUR FOCUSED TA PLANS WILL BE INFORMED BY THE PRIORITIZED PROBLEMS, CONCENTRATED ON ROOT CAUSES OF KEY GAPS, AND WILL BE TAILORED AND ADAPTED FOR OPTIMAL RESULTS THROUGH USE OF M & E DATA. WE WILL PROVIDE TA ACROSS FIVE STRATEGIES: ENHANCING TB SCREENING AND CASE FINDING TO FIND ALL UNDIAGNOSED TB PATIENTS; STRENGTHENING TB TREATMENT DELIVERY TO ENSURE CONTINUITY OF QUALITY TB CARE AMONG ALL TB PATIENTS AND PEOPLE LIVING WITH HIV; SCALING UP TB INFECTION PREVENTION AND CONTROL MEASURES IN HEALTH FACILITIES TO ENSURE SAFE ENVIRONMENTS FOR CLIENTS AND STAFF; SCALING UP TB PREVENTIVE TREATMENT TO INDIVIDUALS WHO ARE CONSIDERED AT RISK OF TB DISEASE; AND ASSESSING AND MITIGATING BARRIERS TO ACCESSING TB SERVICES. THROUGHOUT IMPLEMENTATION, PATH WILL PRIORITIZE IMPROVING THE CAPACITY OF THE NTPS TO ANALYZE DATA FOR DECISION-MAKING. THROUGH THE CLOSE COLLABORATION AND CAPACITY-BUILDING ACROSS THE FIVE STRATEGIES, THE PROJECT WILL INCREASE EVIDENCE-BASED AND DATA-DRIVEN TB PROGRAMMING, THEREBY IMPROVING THE CAPACITY OF HEALTH MINISTRIES TO IMPLEMENT AND OVERSEE TB PREVENTION, DIAGNOSTIC, AND TREATMENT SERVICES. THE WORK WILL ULTIMATELY LEAD TO REDUCING TB TRANSMISSION, MORTALITY, AND MORBIDITY, AND SUSTAINED PROGRESS TOWARD TB-FREE INDIA, TANZANIA, AND ZAMBIA.